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 An accurate test to predict the effectiveness of adjuvant endocrine 
therapy for hormone receptor – positive breast cancer on an indi-
vidual basis would be an important advance ( 1 ). Current approaches 
focus on biomarker analysis of the diagnostic specimen. An alter-
native is to treat patients with an endocrine agent for several 
months before surgery to identify tumors that are responsive to 
treatment, with the assumption that responsiveness indicates a 
lower risk of relapse. However, compared with neoadjuvant che-
motherapy studies ( 2 ), fewer neoadjuvant endocrine therapy trials 
have been conducted; thus, fewer data are available to link post-
neoadjuvant therapy tumor characteristics and survival. 
 The P024 neoadjuvant endocrine therapy trial, which com-
pared 4 months of letrozole and tamoxifen before surgery ( 3 , 4 ), 
now has sufﬁ cient follow-up (median >60 months) to address the 
relationships between postneoadjuvant endocrine therapy tumor 
characteristics and risk of early relapse. In this study, we used 
data from P024 to examine pathological stage posttreatment, 
histological grade posttreatment, response to treatment, and the 
biomarker status of the surgical specimen to develop a prognostic 
model that incorporates standard pathological staging variables 
and “on-treatment” biomarker values. We validated the model 
internally though bootstrap analysis and subsequently validated it 
externally using data from an independent neoadjuvant 
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 ARTICLE 
 Outcome Prediction for Estrogen Receptor – Positive 
Breast Cancer Based on Postneoadjuvant Endocrine 
Therapy Tumor Characteristics 
 Matthew J.  Ellis ,  Yu  Tao ,  Jingqin  Luo ,  Roger  A’Hern ,  Dean B.  Evans ,  Ajay S.  Bhatnagar , 
 Hilary A.  Chaudri Ross ,  Alexander  von Kameke ,  William R.  Miller ,  Ian  Smith ,  
 Wolfgang  Eiermann ,  Mitch  Dowsett 
  Background  Understanding how tumor response is related to relapse risk would help clinicians make decisions about 
additional treatment options for patients who have received neoadjuvant endocrine treatment for estro-
gen receptor – positive (ER+) breast cancer. 
  Methods  Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 
neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before sur-
gery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological 
tumor size, node status, and treatment response. Cox proportional hazards were used to identify factors 
associated with relapse-free survival (RFS) and breast cancer – specific survival (BCSS) in 158 women. A 
preoperative endocrine prognostic index (PEPI) for RFS was developed from these data and validated in 
an independent study of 203 postmenopausal women in the IMPACT trial, which compared treatment with 
anastrozole, tamoxifen, or the combination 3 months before surgery. Statistical tests were two-sided. 
  Results  Median follow-up in P024 was 61.2 months. Patients with confirmed baseline ER+ clinical stage 2 and 3 
tumors that were downstaged to stage 1 or 0 at surgery had 100% RFS (compared with higher stages, 
 P < .001). Multivariable testing of posttreatment tumor characteristics revealed that pathological tumor 
size, node status, Ki67 level, and ER status were independently associated with both RFS and BCSS. The 
PEPI model based on these factors predicted RFS in the IMPACT trial ( P = .002). 
  Conclusions  Breast cancer patients with pathological stage 1 or 0 disease after neoadjuvant endocrine therapy and a 
low-risk biomarker profile in the surgical specimen (PEPI score 0) have an extremely low risk of relapse 
and are therefore unlikely to benefit from adjuvant chemotherapy. 
  J Natl Cancer Inst 2008;100: 1380 – 1388 
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endocrine therapy study that compared anastrozole, tamoxifen, 
or the combination for 3 months before surgery (the IMPACT 
trial) ( 5 , 6 ). 
 Subjects and Methods 
 Study Population and Tumor Bank 
 Both clinical trials described in this manuscript were approved 
by the local institutional review boards that enrolled patients into 
the studies ( 3 , 5 ). The P024 protocol compared 4 months of 
neoadju vant letrozole therapy with 4 months of neoadjuvant 
tamoxifen therapy in postmenopa usal women with clinical stage 
2 and 3 hormone receptor – positive breast cancers (classified as at 
least 10% nuclear staining for estrogen receptor [ER] and/or pro-
gesterone receptor [PgR]) who were ineligible for breast conserva-
tive surgery ( 3 ). The clinical findings, tumor bank characteristics, 
and biomarker measurements have been described previously 
( 3 , 4 , 7 ). The cut point for ER positivity for central laboratory 
analysis was an Allred score of 3 ( 8 ). Information on tumor grade, 
clinical response by caliper measurements, definitive pathological 
staging at surgery , and chemotherapy administration was collected 
prospectively. Patients in P024 were recommended to receive 
adjuvant tamoxifen for 5 years. The IMPACT study design, short- 
and long-term outcomes, and biomarker methodology have also 
been described previously ( 5 , 6 , 9 ). For the validation analysis, we 
compiled information on surgical stage, surgical specimen Ki67 
proliferation antigen levels, ER data, duration of follow-up, and 
relapse dates. The IMPACT study used the H-score ( 10 ) to assess 
ER status. We converted the H-score ER cutoff to an Allred score 
ER cutoff for the analyses. An Allred score of 2 can be derived in 
only one way, ie, less than 1% of cells staining weakly, which 
equates to an H-score of less than 1. Thus, it is valid to use an 
H-score of at least 1 as the equivalent of an Allred score of at least 
3 as the threshold for ER positivity. 
 Statistical Analysis 
 Relapse-free survival (RFS) was defined as the interval between 
random assignment to treatment and the earliest subsequent breast 
cancer event. No new breast primary tumors were documented in 
either dataset, effectively excluding this class of event from the risk 
model that was developed. Breast cancer – specific survival (BCSS) 
was defined as the interval between random assignment and the 
date of death after breast cancer relapse. When we included all 
deaths, irrespective of cause, as RFS and overall survival events, 
there were no major changes in the P024 results (data not shown). 
Survival curves were estimated by the Kaplan – Meier method, and 
a two-sided  P value of .05 from a log-rank test was considered a 
statistically significant difference. A multivariable Cox propor-
tional hazard regression model was used to evaluate the indepen-
dent prognostic relevance of each factor, namely, pathological 
tumor size (T1/2 vs T3/4 or T1 vs T2 – 4), pathological node status 
(negative vs positive), clinical response (complete plus partial clini-
cal response vs stable disease plus progressive disease), surgical 
specimen ER status (Allred score  ≥ 3 vs 0 or 2), histological grade 
(grade 1 vs grade 2/3), and the Ki67 level, as natural log-trans-
formed intervals ( 9 ), in both the pretreatment specimen and the 
surgical specimen.  P values from Wald chi-square tests indicated 
the statistical significance of a factor after adjusting for the other 
factors. The proportionality assumption was checked by testing 
time-dependent covariates in the model and graphically examining 
scaled Schoenfeld residuals. Hazard ratio (HR) estimates of each 
factor in the final multivariable model were used to construct a 
score, the preoperative endocrine prognostic index (PEPI), for risk 
of relapse and breast cancer – specific death for each sample in the 
test cohort. The PEPI score was derived as an arithmetic sum of 
risk points weighted by the size of the HR assigned to each statisti-
cally significant factor ( 11 ). The overall discriminatory capacity of 
the Cox model on the P024 data was assessed using Harrell’s C 
index, which was then adjusted after a 1000 bootstrap assessment 
of the overfitting (optimism) portion. The 95% confidence inter-
val (CI) for the adjusted C index was also reported ( 12 ). For the 
IMPACT trial validation analysis, we calculated the PEPI score for 
all patients who had data for the four factors and examined the 
association of PEPI score with RFS. SAS version 9.02 (SAS 
Institute, Cary, NC) and R 2.6 software (R Foundation for 
Statistical Computing) were used for all analyses. 
 Results 
 Definition of the Patient Populations for Analysis 
 Detailed information on the P024 population used in each of the 
analyses was compiled and is summarized in  Figure 1 . The median 
follow-up was 61.2 months for the patients who underwent sur-
gery at the end of 4 months of endocrine treatment (n = 290) and 
62.0 months for the patients with a complete dataset for the mul-
tivariable analysis (n = 158). Assignment to neoadjuvant letrozole 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Endocrine therapy before surgery increases the rate of breast con-
servation surgery for patients with hormone receptor – positive 
breast cancer, but factors to predict risk of relapse after treatment 
have not been identified. 
 Study design 
 Posttreatment prognostic factors from patients enrolled in clinical 
trials of neoadjuvant endocrine therapy were used to develop and 
validate a model to predict risk of relapse. 
 Contribution 
 A model that includes information on standard surgical staging 
parameters after neoadjuvant endocrine treatment, estrogen recep-
tor status, and levels of Ki67 proliferation antigen can define broad 
relapse risk groups. 
 Implications 
 Data from this model may prove useful with respect to other deci-
sions that must be made after a patient is treated with neoadjuvant 
endocrine therapy, such as the use of adjuvant chemotherapy. 
 Limitations 
 The studies used for developing and validating the model were 
small, used different treatments, and had relatively short median 
follow-up data available (just more than 5 years). 
 From the Editors 
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or tamoxifen had no impact on RFS or BCSS, but because all 
patients received adjuvant tamoxifen a difference was not antici-
pated. Thus, for the purposes of these analyses, the results from 
both arms were pooled together. As described in the original 
report on central laboratory ER testing ( 4 ), 12% of patients had 
ER  tumors at baseline, and of the 28 ER  and PgR  tumors, 
only one was reported to respond to treatment. Long-term 
follow-up confirmed that these tumors were likely to have been 
correctly assigned by the central laboratory because baseline ER  
status was associated with poor overall survival ( P = .004, data not 
shown). Subsequent analysis therefore focused on patients with 
ER+ tumors as assigned by the central laboratory (n = 228). 
 Pathological Stage, Tumor Grade, and Response 
on Outcome 
 All patients had clinical stage 2 or 3 tumor at diagnosis. To exam-
ine the impact of pathological (p) stage on outcome, patients 
whose tumors were downstaged at surgery to pT1N0 (node 
negative with a tumor size of  ≤ 2 cm diameter with negative 
ax illary lymph nodes — stage 1) or pT0N0 (pathological complete 
response — stage 0) were compared with patients with p-stage 2 
or 3 disease at surgery. No relapses and only one death without 
known relapse (which was censored) were recorded in the group 
of 29 patients with p-stage 1 disease plus one patient with p-stage 
0 disease vs 53 of the 175 patients (30% relapse incidence) with 
p-stage 2 and 3 disease ( Figure 2, A ,  P < .001). The p-stage 1 or 0 
status appeared to reflect downstaging of a group of endocrine 
therapy – responsive tumors because the clinical response rate was 
79% in the p-stage 1 or 0 group vs 52% in the p-stage 2 or 3 
group (response rate difference = 27%, 95% CI = 10.5% to 
42.5%;  P = .006). Furthermore, tumors in the p-stage 1 or 0 group 
had lower posttreatment geometric mean Ki67 levels than higher 
p-stage tumors (0.39 vs 0.98, ratio of geometric means = 0.40, 
95% CI = 0.18 to 0.89;  P = .03). The average baseline tumor size 
for the pT1 or pT0N0 tumors was predictably smaller than that 
of tumors with a higher pT stage at surgery; 3.9 vs 5.2 cm (longest 
diameter) by clinical caliper measurement ( P < .001), 2.8 vs 4.0 by 
mammogram ( P < .001), and 2.6 vs 3.4 cm by ultrasound ( P = 
.003). However, given that these average measurements are all 
larger than 2 cm, it is unlikely that many tumors in the P024 study 
  
 Figure 1 .  Patient populations for univari-
ate and multivariable analysis. The patient 
populations are described in this diagram 
to illustrate how the univariable analysis 
sought to include the largest population 
possible. The multivariable analysis was 
performed on a subset of patients among 
whom all factors in the model were 
available for comparison. ER = estrogen 
receptor. 
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were p-stage 1 at diagnosis and therefore likely that p-stage 1 
status usually reflects the effects of tumor regression induced by 
treatment. The excellent outcome in the p-stage 1 or 0 group was 
not strongly influenced by chemotherapy because only 2 of the 30 
(7%) patients with p-stage 1 or 0 disease underwent adjuvant 
chemotherapy vs 61 of 175 (35%) patients with p-stage 2 or 3 
disease ( P = .001). Other factors that were associated with RFS 
in univariate analysis included posttreatment pathological node 
status ( P < .001;  Figure 2, B ), clinical response to treatment ( P = 
.002;  Figure 2, C ), pretreatment grade ( P = .002) (data not shown), 
and posttreatment grade (grade I vs grade II or III,  P < .001;  Figure 
2, D ). The alternative grade dichotomy of grade I or II vs III did 
not have better prognostic characteristics (data not shown). 
 The Association of Posttreatment ER Status with Outcome 
 We had previously noted that a number of tumor samples that were 
ER+ before treatment had lost ER expression in the posttreatment 
sample [ie, converted to an Allred score of 0 or 2, or unequivocally 
  
 Figure 2 .  Kaplan – Meier analysis of relapse-
free survival (RFS) and breast cancer – speciﬁ c 
survival (BCSS) among women whose 
tumors were established to be estrogen 
receptor positive (ER+) at baseline by central 
laboratory analysis.  A ) RFS for posttreatment 
pathological stage 1 or 0 (T1N0 or T0N0, 
 green ) vs higher stages ( red ),  P < .001;  B ) RFS 
for posttreatment pathological node negative 
( green ) vs node positive ( red ),  P < .001; 
 C ) RFS for posttreatment clinical responders 
( green ) vs no clinical response ( red ),  P = .002; 
 D ) RFS for posttreatment histological grade 
(Grade I,  green, vs Grade II/III,  red ),  P < .001. 
 E ) RFS for patients with ER+ tumors post-
treatment ( green ) vs ER negative (  ) tumors 
posttreatment ( red ),  P = .03;  F ) BCSS for 
patients with ER+ tumors posttreatment 
( green ) vs ER  tumors posttreatment ( red ), 
 P = .002; censorship marks are provided as 
 open circles . All  P values (two-sided) were 
calculated using the log-rank test. 
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ER  ( 4 )]. We therefore compared RFS and BCSS between patients 
with tumors that converted from ER+ to ER  and patients with 
tumors that were persistently ER+ at surgery. The 16 patients with 
posttreatment ER  tumors had worse RFS (HR of relapse = 2.4, 
95% CI = 1.0 to 5.3;  P = .03) and BCSS (HR of breast cancer death = 
4.3, 95% CI = 1.6 to 11.7;  P = .002) ( Figure 2, E and F ) than patients 
with tumors that retained ER+ after treatment. The pretreatment 
Allred scores of tumors that were ER  after treatment was similar 
to that of tumors that retained ER expression ( P = .2). 
 The Association of Pre- and Posttreatment Ki67 
Proliferation Index with Outcome 
 Ki67 is a commonly used proliferation antigen that identifies cells 
in the G1/S and M phases of the cell cycle ( 13 ). Ki67 was examined 
as a continuous variable after natural log transformation, as recom-
mended by Dowsett et al. ( 9 ). This analysis approach examines the 
HR per 2.7-fold increase in the Ki67 value (referred to as “natural 
log intervals”). Pretreatment Ki67 natural log intervals were not 
associated with relapse, whereas there was a highly statistically 
significant association between RFS and posttreatment Ki67 natu-
ral log intervals (HR = 1.4, 95% CI = 1.2 to 1.6 per log unit 
increase;  P < .001;  Table 1 ), which also held for BCSS (HR = 1.4, 
CI = 1.1 to 1.7;  P = .009;  Table 2 ). 
 Development of a Multivariable Cox Model 
 Pathological tumor size (T1/2 vs T3/4 or T1 vs T2 – 4), patho-
logical node status (negative vs positive), clinical response (com-
plete plus partial clinical response vs stable disease plus 
 Table 1 .  Univariate and multivariable analysis of relapse-free survival according to posttreatment pathological tumor size, post
treatment node status, posttreatment Ki67 level, posttreatment ER status, and posttreatment tumor grade in the P024 trial * 
 Factor definitions
No. of patients 
in each group
No. of events/no. 
of patients
Relapse-free survival 
 Univariate analysis Multivariable analysis 
 HR (95% CI)  P HR (95% CI)  P 
 Pathological tumor size †  
  T1/2 vs T3/4 138/33 47/171 2.7 (1.4 to 5.0) .002 3.0 (1.54 to 5.91) .001 
  T1 vs T2–4 53/118 47/171 2.01 (1.0 to 4.1) .05  —  
 Node status (positive vs negative) 90/69 44/159 3.9 (1.8 to 8.4) <.001 2.8 (1.31 to 6.19) .009 
 Ki67 level, per 2.7-fold increase ‡  NA 48/174 1.4 (1.2 to 1.6) <.001 1.3 (1.05 to 1.50) .01 
 ER, Allred score (0 or 2 vs 3 – 8) § 16/157 48/173 2.4 (1.0 to 5.3) .04 2.6 (1.1 to 6.0) .03 
 Clinical response (yes vs no) 70/104 49/174 2.8 (1.6 to 4.9) <.001 1.72 (0.96 to 3.09) .07 
 Grade (I vs II/III) 33/126 46/159 3.8 (1.4 to 10.8) .011 2.72 (0.95 to 7.8) .06 
 *  The total number in each univariate analysis varied depending on the number of cases in which information on the individual factor was available. Cox 
proportional hazards models were used to calculate hazard ratios (HRs) and their 95% confidence intervals (CIs) of relapse, comparing tumors with the adverse 
factor relative to tumors without the adverse factor. Two-sided  P values are provided throughout. 
 †  Tumor size was examined with two cutoff points, pT1/2 vs pT3/4 and pT1 vs pT2 – 4. A cutoff point of pT1/2 provided the smallest univariate  P value and was 
used in the multivariable analysis (which excluded factors with a univariate  P value of >.05). 
 ‡  Ki67 was analyzed as the natural logarithm values, or per 2.7-fold increase according to the original scale of percentage values. 
 §  The estrogen receptor (ER) analysis refers to the posttreatment values; before treatment all tumors in this dataset were ER+. 
  NA (not applicable) because K167 divided into five risk groups (see Table 4). 
 Table 2 .  Univariate and multivariable analysis of breast cancer – specific survival according to pathological tumor size, node status, 
posttreatment Ki67, posttreatment ER status, and posttreatment tumor grade in the P024 trial * 
 Factor definition
No. of patients 
in each group
No. of events/no. 
of patients
Breast cancer – specific mortality 
 Univariate analysis Multivariable analysis 
 HR (95% CI)  P HR (95% CI)  P 
 Pathological tumor size †  
  T1/2 vs T3/4 138/33 24/171 3.5 (1.5 to 8.3) .004 4.4 (1.7 to 11.3) .002 
  T1 vs T2–4 53/118 24/171 4.1 (1.2 to 13.8) .025  —  
 Node status (positive vs negative) 90/69 22/159 4.6 (1.4 to 15.8) .01 3.2 (0.9 to 11.2) .07 
 Ki67 level, per 2.7-fold increase ‡ NA 25/174 1.4 (1.1 to 1.7) .009 1.4 (1.1 to 1.8) .02 
 ER, Allred score (0 or 2 vs 3 – 8) § 16/157 25/173 4.3 (1.6 to 11.7) .005 6.3 (2.1 to 18.7) <.001 
 Clinical response (yes vs no) 70/104 25/174 2.2 (0.97 to 4.9) .06 1.1 (0.5 to 2.5) .78 
 Grade (I vs II/III) 33/126 24/159 7.1 (0.96 to 53) .05 4.62 (0.6 to 35.0) .1 
 *  The total number in each univariate analysis varied depending on the number of tumors in which information on the individual factor was available. Cox 
proportional hazards model was used to calculate hazard ratios (HRs) and their confidence intervals (CIs) of relapse, comparing tumors with the adverse 
factor relative to those without the adverse factor. Two-sided  P values are provided throughout. 
 †  Tumor size was examined by two cutoffs, pT1/2 vs pT3/4 and pT1 vs pT2 – 4. A cutoff of pT1/2 provided the smallest univariate  P value and was used in the 
multivariable analysis (which excluded factors with a univariate  P value of >.05). 
 ‡  Ki67 analyzed as the natural-logarithm values, or per 2.7-fold increase according to the original scale of percentage values. 
 §  The estrogen receptor (ER) analysis refers to the posttreatment values; before treatment all the tumors in this dataset were ER+. 
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progressive disease), surgical specimen ER status (Allred score 
 ≥ 3 vs 0 or 2), histological grade (grade I vs grade II/III), and 
Ki67 natural log intervals were used in a multivariable Cox pro-
portional hazard model to determine their association with RFS 
( Table 1 ) and BCSS ( Table 2 ). For Ki67, the posttreatment 
natural log intervals were statistically significantly associated 
with both RFS (per log unit increase, HR of relapse = 1.3, 95% 
CI = 1.05 to 1.50;  P = .01) and BCSS (per log unit increase, HR 
of breast cancer death = 1.4, 95% CI = 1.1 to 1.8;  P = .02). 
Pathological tumor size (pT1/2 vs pT3/4) was strongly associ-
ated with RFS (HR = 3.0, 95% CI = 1.54 to 5.91;  P = .001) and 
BCSS (HR = 4.4, 95% CI = 1.7 to 11.3;  P = .002). Pathological 
node status was also associated with RFS (positive vs negative, 
HR = 2.8, 95% CI = 1.31 to 6.19;  P = .009). ER status posttreat-
ment (Allred score 0 or 2 vs 3 – 8) was also independently associ-
ated with RFS (HR = 2.6, 95% CI = 1.1 to 6.0;  P = .03). For 
BCSS, ER loss stands out as being particularly strongly associ-
ated with poor outcome (HR = 6.3, 95% CI = 2.1 to 18.7;  P < .001). 
Clinical response and grade were not independently associated 
with RFS or BCSS. 
 An Integrated Biomarker Model to Predict Long-term 
Outcome for Patients Treated with Neoadjuvant 
Endocrine Therapy 
 The four factors that were associated with  P values of less than 
.05 in the multivariable analysis (pathological tumor size, patho-
logical node status, ER status, and Ki67 natural log intervals — all 
derived from the surgical specimen analysis) were promoted to 
the next analysis phase, which focused on developing a prognos-
tic classification schema. For the first step in model building, the 
four statistically significant risk factors were reanalyzed by Cox 
proportional hazards to derive a “final” HR associated with each 
factor ( Table 3 ). Risk points were then applied using an approach 
used for the development of prognostic models in cardiovascular 
disease to weight the different prognostic strengths associated 
with the final HRs assigned to each factor ( Table 4 ) ( 11 ). The 
scoring process outlined in  Table 4 produced three groups (risk 
score 0, 1 – 3, and  ≥ 4) that were associated with relapse risks of 
10%, 23%, and 48% ( P < .001;  Figure 3, A ). For breast cancer 
death, the risk was 2%, 11%, and 17% ( P < .001;  Figure 3, B ). 
For RFS, the C index for the four-component model after 
adjustment for overfitting was 0.723 (95% CI = 0.67 to 0.82). For 
BCSS, the adjusted C index was 0.78 (95% CI = 0.71 to 0.91). 
These C indices are within the range that defines a clinically 
valuable prognostic model, which we termed “PEPI” for preop-
erative endocrine prognostic index. 
 Independent Validation of the PEPI Model 
 We sought to validate the PEPI model in the IMPACT study, a 
neoadjuvant endocrine therapy trial with short-term endpoints 
similar to those of the P024 trial ( 6 ). Data on pathological stage, 
ER status, and Ki67 intervals were available from 203 surgical 
specimens. The model produced a statistically significant separa-
tion of the three PEPI risk groups (risk score 0, 1 – 3, and  ≥ 4), 
indicating that the model is valid ( Figure 3, C ) ( P = .002). As with 
the P024 study, IMPACT patients with p-stage 1 or 0 disease had 
a more favorable outcome than patients with p-stage 2 or 3 disease 
( P = .03;  Figure 3, D ). Of particular note, there were no recorded 
relapses in either study for the p-stage 1 or 0 group with a PEPI 
risk score of 0, with a combined median follow-up of 60.3 months 
(range = 4.5 – 86.5 months). 
 To determine the potential inﬂ uence of adjuvant chemo-
therapy on the RFS estimates in the PEPI score, the use of 
 Table 3 .  Multivariable Cox proportional hazards analysis of 
relapse-free survival (RFS) and breast cancer – specific survival 
(BCSS) from the P024 trial * 
 Pathology 
biomarker and 
response factors
RFS
 HR (95% CI)  P 
BCSS 
HR (95% CI)  P 
 Pathological tumor 
 size (T1/2 vs T3/4)
2.8 (1.4 to 5.4) .003 4.4 (1.7 to 11.2) .002 
 Node status 
 (positive vs 
 negative)
3.2 (1.5 to 6.9) .004 3.9 (1.1 to 13.7) .04 
 Ki67 level per 
 2.7-fold increase
1.3 (1.1 to 1.6) .003 1.4 (1.07 to 1.9) .01 
 ER, Allred score 
 (0 or 2 vs 3 – 8)
2.8 (1.2 to 6.4) .02 7.0 (2.4 to 20.9) <.001 
 *  The four factors associated with a  P value of .05 or less for RFS in  Table 1 
were reanalyzed in a Cox model to assign final hazard ratios for risk of 
relapse (RFS) and breast cancer mortality (BCSS). ER = estrogen receptor; 
HR = hazards ratio; CI = confidence interval. 
 Table 4 .  The preoperative endocrine prognostic index * 
 Pathology, biomarker 
status
RFS BCSS 
 HR Points HR Points 
 Pathological tumor size   
  T1/2  — 0  — 0 
  T3/4 2.8 3 4.4 3 
 Node status  
  Negative  — 0  — 0 
  Positive 3.2 3 3.9 3 
 Ki67 level  
  0% – 2.7% (0 – 1 † )  — 0  — 0 
  >2.7% – 7.3% (1 – 2 † ) 1.3 1 1.4 1 
  >7.3% – 19.7% (2 – 3 † ) 1.7 1 2.0 2 
  >19.7% – 53.1% (3 – 4 † ) 2.2 2 2.7 3 
  >53.1% (>4 † ) 2.9 3 3.8 3 
 ER status, Allred score  
  0 – 2 2.8 3 7.0 3 
  3 – 8  — 0  — 0 
 *  To obtain the preoperative endocrine prognostic index (PEPI) score, risk 
points for relapse-free survival (RFS) and breast cancer – specific survival 
(BCSS) were assigned depending on the hazard ratio (HR) given in  Table 3 . 
The points scale was adapted from the cardiovascular literature on predict-
ing outcomes for myocardial infarction ( 11 ). The total PEPI score assigned to 
each patient is the sum of the risk points derived from the pT stage, 
pN stage, Ki67 level, and estrogen receptor (ER) status of the surgical speci -
men. An HR in the range of 1 – 2 receives one risk point; a HR in the 2 – 2.5 
range, two risk points; a HR greater than 2.5, three risk points. The total risk 
point score for each patient is the sum of all the risk points accumulated 
from the four factors in the model. For example, a patient with a T1N0 tumor, 
a Ki67 staining percentage of 1 and an ER Allred score of 6 will have no risk 
points assigned. In contrast, a patient with a T3N1 tumor, a Ki67 
staining percentage of 25, and an ER Allred score of 2 will have a total 
relapse score of 3 + 3 + 2 + 3 = 11. 
 †  The natural logarithm interval corresponding to the percent Ki67 values on 
the original percentage scale. 
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adjuvant chemotherapy was tabulated by PEPI risk group for 
both studies ( Figure 3, E [P024] and  F [IMPACT]). The per-
centages of patients who were treated with chemotherapy in 
PEPI group 1 (no risk points) were 12% (P024) and 3% 
(IMPACT ), too low for chemotherapy to have had a major role 
in producing the favorable outcomes observed in this group. 
The heat maps in  Figure 3 , E and F, serve to display the distri-
bution of adverse factors in the two studies. These data illustrate 
the mixed nature of the intermediate group of tumors (PEPI 
score 1 – 3), which consisted of either low-stage tumors with 
adverse biomarkers or higher-stage tumors with favorable bio-
markers. Ultimately, the clinical signiﬁ cance of the PEPI model 
lies in its ability to identify patients at low risk of relapse in the 
absence of adjuvant chemotherapy (group 1) and patients at very 
high relapse risk that should mandate all appropriate adjuvant 
treatments (group 3). More conﬁ dence around the estimates of 
relapse risk assigned to PEPI group 2 will require studies with 
larger sample sizes and longer follow-up. Finally, because of the 
shorter follow-up, there were too few deaths in the IMPACT 
trial to validate the PEPI model for the prediction of BCSS. 
 Discussion 
 Neoadjuvant endocrine therapy has been widely adopted as a prac-
tical means to improve surgical outcomes for postmenopausal 
women with ER+ stage 2 and 3 breast cancer ( 14 ), but little was 
known about how the post–neoadjuvant endocrine therapy patho-
logical stage and biomarker status could be used to make decisions 
regarding other adjuvant treatments. To address this question, we 
integrated information on standard pathological staging parame-
ters after neoadjuvant endocrine therapy with measurements of ER 
status and levels of the Ki67 proliferation antigen in the surgical 
 Figure 3 .  Development and validation of the 
Preoperative Endocrine Prognostic Index (PEPI). 
 A ) Relapse-free survival (RFS) for the three PEPI 
risk groups identiﬁ ed in the P024 model with a 
log-rank statistic to test the overall trend ( P < 
.001). The  green line represents group 1, patients 
with a PEPI risk score of 0; the  red line group 2, 
a PEPI risk score of 1 – 3; and the  purple line 
group 3, a PEPI risk score of 4 or more. The three 
groups have distinct risks of relapse.  B ) PEPI 
groups 1, 2, and 3 also have distinct risks of 
breast cancer death, with similar statistical sig-
niﬁ cance as the RFS data ( P < .001).  C ) The PEPI 
model was validated in the IMPACT trial for 
RFS, with a statistically signiﬁ cant association 
between relapse risk and risk score ( P = .002). 
 D ) Pathological stage (stage 1 or 0 [ green line ] 
vs stage 2 or 3 [ red line ]) has a distinctly favor-
able outcome in the IMPACT trial ( P = .03). Of 43 
patients in the stage 1 or 0 group, only one 
experienced relapse. This patient’s tumor had 
the highest Ki67 level in the stage 1 or 0 group, 
and had therefore been correctly assigned to 
PEPI group 2.  E ) Top, relationships among risk 
score, relapse events, and adjuvant chemother-
apy administration (Chemo) in patients in the 
P024 trial. Bottom, heat map summarizing 
the distribution of the individual components of 
the risk score.  F ) Top, relationships among risk 
score, relapse events, and adjuvant chemother-
apy administration (Chemo) in patients in the 
IMPACT trial. Bottom, heat map summarizing 
the distribution of the individual components of 
the risk score. The heat maps indicate the pres-
ence of a favorable factor ( green ) or an adverse 
factor ( red ) for large tumor size, node-positive 
status, or estrogen receptor (ER) negativity. The 
color coding in the Ki67 line of the heat map 
indicates Ki67 with a risk point of 0 as  green , a 
risk point of 1 as  dark red , and risk point of 2 as 
 red . The  bar over the heat map indicates the 
three risk groups generated by the risk point 
assignments ( green , group 1;  red, group 2; and 
 purple, group 3). 
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specimen to create the PEPI score that weights these factors 
according the magnitude of the HR. Of particular note, patients 
with low pathological stage (stage 1 or 0) and a favorable biomarker 
profile (PEPI score 0) at surgery had such a low rate of relapse that 
further adjuvant systemic therapy beyond continuation of an endo-
crine agent appears unnecessary. In striking contrast, patients with 
high pathological stage disease at surgery and a poor biomarker 
profile (PEPI group 3) had a statistically significant higher risk of 
early relapse, more typical of ER  disease, and therefore should be 
offered all appropriate adjuvant treatments available. 
 The biomarker analysis we have presented here would clearly 
beneﬁ t from additional retrospective studies of tumor samples from 
other patients who were treated in a similar fashion, with longer 
follow-up. Prospective validation studies are also warranted to con-
ﬁ rm the PEPI as a tool for individualization of adjuvant chemo-
therapy treatment. As part of these investigations, further study of 
the PEPI group 2 to more clearly deﬁ ne relapse risk categories 
would greatly improve the model. For example, a larger sample size 
could further deﬁ ne the risk of relapse associated with modest eleva-
tions of Ki67 above 2.7% in pathological stage 1 and 2A disease. An 
ideal prospective validation study would include an immediate-sur-
gery control arm to directly compare a standard adjuvant chemo-
therapy decision-making approach vs pathological staging and tumor 
biomarker proﬁ ling after neoadjuvant endocrine therapy. Pending 
the results from such a trial, we can state with conﬁ dence that analy-
sis of post–neoadjuvant endocrine therapy surgical samples with 
Ki67 and ER provides additional useful prognostic information that 
is not provided by an analysis of the baseline sample alone. Repeat 
ER analysis reveals the presence of a subset of tumors with unstable 
ER expression and very aggressive clinical course. “On-treatment” 
Ki67 levels more accurately predict relapse risk than baseline values, 
whether measured at 3 – 4 months, as discussed in this study, or as 
early as 2 weeks after initiaton of endocrine treatment, as shown 
earlier by the IMPACT investigators ( 9 ). A standardized ER and 
Ki67 analysis approach should be adopted as part of any prospective 
plan to validate the PEPI model as a clinical decision tool. 
 The data presented may prove useful with respect to other deci-
sions that must be made when a patient is treated with neoadjuvant 
endocrine therapy. For example, nodal stage after neoadjuvant 
endocrine therapy was powerfully predictive, suggesting that 
upfront staging of the axillary nodes may not be necessary before 
initiation of neoadjuvant endocrine treatment because the prog-
nostic impact of this factor is preserved after therapy. In addition, 
the PEPI score might be used to tailor radiotherapy decisions. 
That is, in the setting of a favorable PEPI score and low pathologi-
cal stage, it might be appropriate to consider partial breast irradia-
tion, or even no radiation, as part of a prospective study ( 15 ). The 
ER and Ki67 data in the present study suggests that prognostic 
tests that contain signatures for proliferation, ER and ER regulated 
genes, such as the 21 gene recurrence score (16) or the distinction 
between Luminal A and luminal B tumors ( 17 ) may have additional 
valuable qualities when applied to samples that have been exposed 
to endocrine treatment. Speciﬁ cally, tumors that lose the prolifera-
tion gene expression signature in response to endocrine therapy 
would be expected to have a better prognosis than tumors in which 
the proliferation signature persisted despite treatment. In contrast, 
tumors that lose aspects of the luminal signature, particularly ER, 
would be expected to have a worse prognosis because these tumors 
have not maintained the pathway required to respond to endocrine 
therapy after treatment had been initiated ( 18 ). 
 In addition to consideration of the PEPI approach as a tool for 
treatment individualization, the data presented also strongly sup-
port clinical trials in the neoadjuvant setting that study the effects 
of novel endocrine therapy agents and combinations on short-term 
endpoints, such as Ki67 and pathological downstaging, as a prelude 
to large adjuvant trials ( 19 ). 
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